Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with CYP450 2C9 inhibitors may increase the plasma concentration of meloxicam, which has been shown to be primarily metabolized by this isoenzyme. In a study of healthy volunteers, voriconazole, a weak CYP450 2C9 inhibitor increased the systemic exposure of meloxicam by 47% and prolonged the average meloxicam half-life by 51%.

MANAGEMENT: The potential for an interaction should be considered during concomitant use. If coadministration is required, monitor patients for NSAID-related side effects and toxicity including gastrointestinal bleeding or perforation. Dose adjustment of meloxicam may be warranted.

Zafirlukast should be taken on an empty stomach 1 hour before or 2 hours after a meal unless otherwise directed by your doctor. You may experience reduced absorption of zafirlukast in the presence of food. This will make it easier for your body to absorb the medication.